Pfizer has notified the FDA that there may be an impending shortage of penicillin, citing an increase in syphilis infections and other shortages.
In a letter posted to the FDA’s website and dated Monday, the pharma said there is “limited supply” and an “impending stock out situation” for prefilled Bicillin L-A and Bicillin C-R syringes, which are also used to treat pneumonia, strep throat and other bacterial infections. To alleviate the possible shortage, Pfizer said it’s prioritizing the production of Bicillin L-A prefilled syringes, according to a Pfizer spokesperson.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.